Volitionrx LTD Form 4 insider transactions

VolitionRx's General Counsel, Nicholas Plummer, vested 44,700 restricted stock units, adding to his direct beneficial ownership.

VolitionRx Ltd. Director Mickie Henshall reported the vesting of 12,000 restricted stock units, increasing her direct beneficial ownership to 44,206 shares.

VOLITIONRX LTD Director Kim Nguyen acquired 12,000 shares of common stock through the partial vesting of restricted stock units, increasing direct beneficial ownership.

Jasmine Kway, CEO of VolitionRx Singapore, reported the vesting of 42,000 restricted stock units and the cancellation of 98,000 units.

VolitionRx CEO Cameron John Reynolds reported a planned acquisition of 20,000 common shares at $0.35 per share, effective November 17, 2025, under a Rule 10b5-1 plan.

VolitionRx's Chief Medical Officer, Andrew Retter, had shares withheld for tax obligations related to the vesting of restricted stock units.

VolitionRx GC Nicholas Plummer's Form 4 filing details the withholding of 5,647 common shares for tax obligations related to RSU settlement.

VolitionRx's Secretary, Rodney Gerard Rootsaert, had 3,197 shares withheld by the company to cover tax obligations related to the settlement of restricted stock units.

VolitionRx's CEO of Veterinary, Salvatore Thomas Butera, had 4,648 shares withheld for tax obligations upon restricted stock unit settlement.

VolitionRx's Chief Commercial Officer, Gael Forterre, had 1,753 shares withheld for tax obligations upon the vesting of restricted stock units.

VolitionRx's President and CEO, Cameron John Reynolds, acquired 110,000 shares and accompanying warrants in a public offering, increasing his direct beneficial ownership.

VolitionRx Director Guy Archibald Innes acquired 96,153 shares of common stock and accompanying warrants in a public offering, increasing his direct beneficial ownership.

VOLITIONRX LTD Director Timothy Still acquired 48,076 common shares and an equal number of warrants in a public offering.

VolitionRx's Group Chief Marketing Officer, Ann-Louise Batchelor, had 6,110 shares withheld by the company to cover tax obligations upon the settlement of 13,000 restricted stock units.

VolitionRx's CEO of Volition Veterinary, Salvatore Thomas Butera, had 5,834 shares withheld by the company to cover tax obligations related to the vesting of 21,333 restricted stock units.

VolitionRx's Secretary, Rodney Gerard Rootsaert, reported a disposition of 4,620 common shares to cover tax obligations related to the vesting of 11,000 restricted stock units.

VolitionRx's Chief Commercial Officer, Gael Forterre, had 5,389 shares withheld by the company to cover tax obligations related to restricted stock unit settlement.

Nicholas Plummer, GC of Volition Diagnostics, had 8,146 shares withheld by VolitionRx to cover tax obligations from restricted stock unit vesting.

VolitionRx's Chief Operating Officer, Gaetan Michel, had 12,333 shares withheld by the company to cover tax obligations related to the vesting of 24,666 restricted stock units.

VolitionRx's Chief Scientific Officer, Jacob Vincent Micallef, reported a disposition of 5,850 common shares to satisfy tax withholding obligations related to restricted stock unit settlement.

VolitionRx Secretary Rodney Rootsaert reported a disposition of 4,158 common shares for tax withholding related to restricted stock unit settlement.

Salvatore Thomas Butera, CEO of Volition Veterinary, reported the disposition of 5,230 VolitionRx common shares for tax withholding related to restricted stock unit settlement.

VolitionRx's Chief Scientific Officer, Jacob Vincent Micallef, reported a disposition of 5,568 common shares for tax withholding related to restricted stock unit settlement.

VolitionRx's Group Chief Marketing Officer, Ann-Louise Batchelor, reported a transaction for tax withholding related to restricted stock unit settlement.

VolitionRx's Chief Operating Officer, Gaetan Michel, had 11,362 shares withheld by the company to cover tax obligations related to the vesting of 22,725 restricted stock units.

VolitionRx's Chief Commercial Officer, Gael Forterre, had 5,503 shares withheld for tax obligations related to the settlement of 13,725 restricted stock units.

VolitionRx CEO Cameron John Reynolds reported a planned acquisition of 15,000 shares of common stock at $0.659 per share, scheduled for September 12, 2025.

VolitionRx Ltd. Secretary Rodney Gerard Rootsaert received an award of 15,223 restricted stock units in lieu of cash compensation, vesting through early 2026.

VolitionRx Director Kim Nguyen was awarded 17,424 restricted stock units in lieu of cash compensation, aligning her interests with shareholders.

VolitionRx's Chief Financial Officer, Terig Hughes, received 26,143 restricted stock units in lieu of cash compensation.